Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Clinical Study Center, Birmingham, Alabama Clinical Study Center, Boston, Massachusetts Clinical Study Center, Charleston, South Carolina Australia
Clinical Study Center, Adelaide Clinical Study Center, Fitzroy Ireland
Clinical Study Center, Dublin Netherlands
Clinical Study Center, Leiden New Zealand
Clinical Study Center, Auckland Clinical Study Center, Hamilton United Kingdom
Clinical Study Center, London Clinical Study Center, Southampton